During the last session, Pulmonx Corp (NASDAQ:LUNG)’s traded shares were 0.41 million, with the beta value of the company hitting 0.63. The 52-week high for the LUNG share is $14.84, that puts it down -72.96 from that peak though still a striking 36.36% gain since the share price plummeted to a 52-week low of $5.46. The company’s market capitalization is $335.91M, and the average intraday trading volume over the past 10 days was 0.31 million shares, and the average trade volume was 324.60K shares over the past three months.

Pulmonx Corp (LUNG) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. LUNG has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.45.

Pulmonx Corp (NASDAQ:LUNG) trade information

The stock’s 5-day price performance is 3.25%, and it has moved by 18.67% in 30 days. Based on these gigs, the overall price performance for the year is -18.67%. The short interest in Pulmonx Corp (NASDAQ:LUNG) is 1.58 million shares and it means that shorts have 4.57 day(s) to cover.

The consensus price target of analysts on Wall Street is $11, which implies an increase of 22.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $20 respectively. As a result, LUNG is trading at a discount of -133.1% off the target high and 30.07% off the low.

Pulmonx Corp (LUNG) estimates and forecasts

Statistics show that Pulmonx Corp has underperformed its competitors in share price, compared to the industry in which it operates. Pulmonx Corp (LUNG) shares have gone down -8.63% during the last six months, with a year-to-date growth rate less than the industry average at -2.50% against 22.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -15.40% this quarter and then drop -30.60% in the quarter after that. In the rating firms’ projections, revenue will increase 20.30% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 20.29M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 22.71M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 16.39M and 19.28M respectively. In this case, analysts expect current quarter sales to grow by 23.80% and then jump by 17.80% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -25.16%. While earnings are projected to return -4.62% in 2024, the next five years will return 23.60% per annum.

LUNG Dividends

Pulmonx Corp is due to release its next quarterly earnings on 2024-Oct-28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Pulmonx Corp (NASDAQ:LUNG)’s Major holders

Pulmonx Corp insiders own 5.21% of total outstanding shares while institutional holders control 94.12%, with the float percentage being 99.29%. PRIMECAP MANAGEMENT CO/CA/ is the largest shareholder of the company, while 158.0 institutions own stock in it. As of 2024-06-30, the company held over 5.71 million shares (or 14.7787% of all shares), a total value of $36.2 million in shares.

The next largest institutional holding, with 5.28 million shares, is of FMR LLC’s that is approximately 13.6686% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $33.48 million.